-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is the original of Translational Medicine Network, please indicate the source of reprinting
Written by Sophia
Colorectal cancer is one of the most common malignancies in the
world.
About 40% of these patients present with early-stage colorectal cancer (stage I or II), most of which can be clinically cured by radical surgery, but 20-25% of patients still die due to tumor recurrence, and it is critical
to identify these patients and give adjuvant chemotherapy after surgery.
At present, the identification of these patients mainly depends on clinical-pathological risk factors, including intestinal obstruction, tumor perforation, number of lymph node dissection, tumor differentiation, vascular cancer thrombus, nerve bundle invasion, microsatellite steady state, etc
.
Recently, the team of Wang Jianping, Luo Yanxin and Yu Huichuan of the Department of Colorectal Surgery and Gastrointestinal Research Institute of the Sixth Affiliated Hospital of Sun Yat-sen University completed an international multi-center study
.
By studying methylation in CpG-deficient regions, a little-known "dark matter" in the epigenome, a novel molecular marker panel MePEC
was developed that can accurately identify the risk of early colorectal cancer recurrence.
The paper was published in the Journal of the National Cancer Institute, an international authoritative journal in oncology, entitled "DNA Methylation Profile in CpG-depleted Regions Uncovers a High-risk Subtype of Early-stage Colorectal Cancer".
That is, the risk of recurrence of early colorectal cancer based on the methylation map of CpG deficiency regions
.
https://academic.
oup.
com/jnci/advance-article-abstract/doi/10.
1093/jnci/djac183/6726193?redirectedFrom=fulltext&login=false
MePEC typing
01
The study lasted a total of 7 years, and MePEC typing can accurately assess the recurrence risk of early colorectal cancer, and the risk ratio is close to 3, that is, the risk of recurrence is 3 times
higher in bowel cancer patients with high MePEC classification.
The study found that patients with MePEC-H have a higher risk of recurrence, and this research will improve the current clinical-pathological risk stratification system and inform
treatment decisions for early colorectal cancer.
Professor Paul Romesser of Memorial Sloan Kettering Cancer Center in the United States wrote an editorial for the paper: "MePEC typing developed in this study can be widely applied in clinical practice in a cost-effective manner; MePEC, which classifies the recurrence risk of early-stage colorectal cancer, has been validated in an international multicenter cohort of diverse populations
.
Another contribution of the research is the development and application of novel methylation detection methods, which overcome the technical limitations of previous methylation studies and greatly facilitate future research on
tumor methylation markers.
DNA methylation profile
02
It is worth mentioning that the detection of this new marker adopts the third-generation methylation-specific PCR technology independently developed by the team - QASM, which can realize the methylation detection of CpG sites at single-base resolution and solve the problem
of methylation PCR quantification in genomic CpG-deficient regions.
The research team constructed DNA methylation profiles specific for tumors and recurrence, and found that there was a huge difference between methylation characteristics that performed well in tumor screening and diagnosis and those that performed well in the prediction of tumor recurrence, and methylation characteristics in CpG-deficient regions were more effective in predicting recurrence than CpG-enriched regions, which changed the previous understanding
of tumor markers.
DNA methylation profiles of CpG-deficient regions associated with colorectal cancer recurrence
Accurate forecasting
03
Based on these findings, the team used machine learning methods to construct MePEC typing, then used QASM technology to achieve rapid, flexible and economical detection, and finally multi-national scholars worked together to complete the application and verification: to achieve accurate prediction
of high recurrence risk in patients with early colorectal cancer.
MePEC classification can be used to distinguish early colorectal cancer patients with different recurrence risks, identify patients who can benefit from adjuvant therapy and close follow-up, provide valuable information for diagnosis and treatment decisions of early colorectal cancer patients, and also provide more accurate segmentation
based on the current molecular classification of colorectal cancer.
Resources:
style="margin-bottom: 15px;white-space: normal;box-sizing: border-box;" _msthash="251156" _msttexthash="9777768">https://academic.
oup.
com/jnci/advance-article-abstract/doi/10.
1093/jnci/djac183/6726193?redirectedFrom=fulltext&login=false
Note: This article is intended to introduce the progress of medical research and cannot be used as a reference
for treatment options.
If you need health guidance, please go to a regular hospital
.
Recommendations, live streams/events
October 21 14:00-17:30 Shanghai
Brain nervous system disease diagnosis and drug discovery industry salon
Scan the QR code to participate for free
Nov 01-02 09:00-17:30 Chongqing
The first Southwest Single Cell Omics Technology Application Forum
Scan the QR code to participate for free
November 25-27 09:00-17:30 Shanghai
The 4th Shanghai International Cancer Congress
Scan the code to participate
